Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
EPN3 enhances EGFR signalling by promoting its recycling and stability, contributing to NSCLC progression and TKI resistance. Targeting EPN3 could offer a novel therapeutic strategy to overcome drug resistance in EGFR-driven NSCLC.
Authors
- Juan Lai
- Wanyu Deng
- Bo Qin (ORCID: https://orcid.org/0000-0002-2300-2397)
- Qian Wang (ORCID: https://orcid.org/0009-0000-6276-9120)
- Yue Zhao (ORCID: https://orcid.org/0000-0001-8410-5210)
- Min Guo (ORCID: https://orcid.org/0000-0003-4945-5877)
- Jie Shen (ORCID: https://orcid.org/0000-0002-3845-2040)
- Jie Dou (ORCID: https://orcid.org/0000-0003-1100-8318)
- Chenzi Gao
- Xin Zhang (ORCID: https://orcid.org/0000-0001-6036-2685)
- Huiling Su
Institutions
- Shangrao Normal University (CN)
- China Pharmaceutical University (CN)
- Bioscience (China) (CN)
- Shaoxing City Women and Children Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Cell & Bioscience
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1186/s13578-025-01358-1
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Guangdong Province Introduction of Innovative R&D Team